MTOR and neoplasm with perivascular epithelioid cell differentiation: In our report, we present a case of a metastatic PEComa patient who progressed on mTOR inhibitor therapy with clinical benefit after treatment with VEGFR-TKI in combination with a PD-1 inhibitor, with a disease control time of 13 months.